Royalty Pharma's EBIT per Share for the
three
months ended in Mar. 2026 was €0.87.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €2.61.
During the past 12 months, the average EBIT per Share Growth Rate of Royalty Pharma was -8.10% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 9.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -9.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Royalty Pharma's EBIT per Share or its related term are showing as below:
FRA:RPD'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -34.2 Med: -8.9 Max: 18.6
Current: 9.5
During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Royalty Pharma was 18.60% per year. The lowest was -34.20% per year. And the median was -8.90% per year.
FRA:RPD's 3-Year EBIT Growth Rate is ranked worse than 56.88% of 1178
companies
in the Biotechnology industry
Industry Median: 15.55
vs FRA:RPD: 9.50
Royalty Pharma's EBIT for the
three
months ended in Mar. 2026 was €486 Mil.
Royalty Pharma (FRA:RPD) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Royalty Pharma EBIT per Share Related Terms
Royalty Pharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for Royalty Pharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.61
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma (FRA:RPD) has a EBIT per Share of €2.61 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Royalty Pharma and its competitors. According to the industry distribution chart, Royalty Pharma ranks #670 out of 1178 companies in the Biotechnology industry, placing it in the top 56.9%.
Is Royalty Pharma's EBIT per Share too high?
Royalty Pharma's current EBIT per Share is €2.61. Based on the distribution chart, Royalty Pharma ranks #670 out of 1178 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Royalty Pharma has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's EBIT per Share compare to ROIV and MRNA?
According to the Biotechnology industry distribution chart, Royalty Pharma ranks #670 out of 1178 companies for EBIT per Share. This places Royalty Pharma in the lower half of its industry. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,178 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Royalty Pharma and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Royalty Pharma's current EBIT per Share is €2.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (FRA:RPD) is currently considered Significantly Overvalued. The stock's GF Value™ is €32.39, compared to a current price of €49.47 — trading 52.7% above its estimated fair value. The current EBIT per Share is €2.61. Royalty Pharma's overall GF Score™ is 68/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Royalty Pharma (FRA:RPD), the current EBIT per Share is €2.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Royalty Pharma (FRA:RPD) Overvalued in 2026?
Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued.
The current stock price of €49.47 is trading 52.7% above its estimated GF Value™ of €32.39.
GuruFocus considers Royalty Pharma to be Significantly Overvalued.
Key valuation signals for FRA:RPD:
EBIT per Share: €2.61
GF Value™: €32.39 vs. price of €49.47 (52.7% above fair value)
No single metric tells the full story. See the FRA:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
68GF Score
Get the complete analysis for FRA:RPD
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RPD has been successfully added to your 
